Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116261 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Sara Nyback und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden. Hauptthemen laut MEDLINE: Tamoxifen, Postmenopause, Vagina, Vaginal Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Percy Falks Foundation for Research into Prostate Cancer and Breast Cancer, Percy Falk Foundation, Magnus Bergvalls Stiftelse.
Abstract (Originalsprache)
BACKGROUND: There is a great need for non-estrogenic treatment of vulvovaginal atrophy (VVA) symptoms affecting sexual function and quality of life. Women with breast cancer on anti-estrogenic therapy are particularly vulnerable and in need of help. The primary aim of this proof-of-concept trial was to evaluate the efficacy of vaginal tamoxifen in reducing the most troublesome VVA symptom. METHODS: In this randomized, double blind, placebo-controlled study, 115 postmenopausal women, with or without breast cancer, were randomized to 20 mg vaginal tamoxifen once weekly or placebo (1:1). Follow-up after one and three-months of treatment, included self-reported VVA symptoms on the Endocrine Symptom Subscale of FACT-B, and gynecologic exams for VVA score and measurement of vaginal pH and endometrial thickness. FINDINGS: After three months, 37 (68.6 %) of women on vaginal tamoxifen reported their most troublesome VVA symptom to be mild or not present at all, whereas corresponding number in the placebo group was 5 (9.1 %), p < 0.001. Expressed as odds, women on vaginal tamoxifen were more likely to report no or minor symptoms after three-months, OR 21.76 (95 % CI 7.36 - 64.3). The improvement in self-reported outcomes was accompanied by improvements in VVA scores and vaginal pH, p < 0.001. INTERPRETATION: This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, Sweden.
- Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden. Electronic address: theodora.kunovac_kallak@uu.se.
Förderung
- Percy Falks Foundation for Research into Prostate Cancer and Breast Cancer
- Percy Falk Foundation
- Magnus Bergvalls Stiftelse
- Cancerfonden
- Swedish Cancer Foundation
Zitieren
APA
Nyback, S., Poromaa, I. S., Lindman, H., Hirschberg, A. L., Kallner, H. K., Wikman, A., & Kallak, T. K. (2026). Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116261
Vancouver
Nyback S, Poromaa IS, Lindman H, Hirschberg AL, Kallner HK, Wikman A, et al. Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116261
BibTeX
@article{Nyback2026,
author = {Nyback, Sara and Poromaa, Inger Sundström and Lindman, Henrik and Hirschberg, Angelica Lindén and Kallner, Helena Kopp and Wikman, Anna and Kallak, Theodora Kunovac},
title = {Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116261}
}
EUVIMED